BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
See today's BioWorld Asia
Home
» Sperogenix licenses China rights to Santhera DMD candidate in $124M deal
To read the full story,
subscribe
or
sign in
.
Sperogenix licenses China rights to Santhera DMD candidate in $124M deal
Jan. 11, 2022
By
Doris Yu
No Comments
Sperogenix Therapeutics Ltd. has acquired exclusive greater China rights to Santhera Pharmaceuticals Holding AG’s glucocorticoid analogue vamorolone in a deal worth up to $124 million.
BioWorld Asia
Deals and M&A
Musculoskeletal
China
